Project Grant R01MD021106
- The National Institute on Aging, part of the Department of Health and Human Services, awarded H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. $463,375 on June 15, 2026, under the Aging Research program (CFDA 93.866, Project Grant R21AG100933) to investigate how aging of the lung tissue microenvironment drives non-small-cell lung cancer evolution and resistance to chemotherapy. The research addresses age-related changes in tumor microenvironment composition and function, with...
- The National Institute for Minority Health and Health Disparities awarded The University of Chicago $1,307,468 on July 19, 2026, under the Minority Health and Health Disparities Research program (CFDA 93.307) to elucidate novel epigenetic contributions to multiple myeloma risk disparities between African American and European American populations. The research investigates cytosine modifications—specifically 5-hydroxymethylcytosines (5HMC)—in circulating cell-free DNA as drivers of the 2- to...
- Federal Grant Award Summary H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. received a $2.99 million Project Grant from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded on September 23, 2025, with a completion date of August 31, 2029. This grant funds research to characterize lung cancer screening (LCS) trends and outcomes among people with HIV (PWH) in the United States, addressing a significant gap in empirical...
- The National Cancer Institute awarded H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. $682,495 under the Cancer Biology Research program (CFDA 93.396) on June 1, 2026. The research characterizes the SPOP-BRAF-mTORC1 signaling axis in melanoma pathogenesis, with focus on understanding BRAF regulation through proteolytic and non-proteolytic polyubiquitination, lysine-acetylation, and AURKA-mediated phosphorylation. The project investigates mechanisms by which SPOP inactivation...
- The National Cancer Institute awarded Mayo Clinic $558,016 on May 8, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate accelerated biological aging and immunosenescence as drivers of racial disparities in monoclonal gammopathy of undetermined significance (MGUS). The funded research examines why multiple myeloma and its precursor condition MGUS occur at disproportionately high rates and younger average ages in individuals of African ancestry. The project tests the...
- The National Cancer Institute awarded H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. $607,249 on May 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to define the role of MAFG in melanocyte transformation and melanoma development. The research investigates non-genetic mechanisms driving melanoma initiation and progression, specifically focusing on the transcription factor MAFG. The work addresses the cell biological and molecular influence of...
- H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. received a $798,673 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) on July 15, 2025, with an ultimate completion date of June 14, 2029. The award funds research to characterize the role of aberrant FGD1 splicing in brain and bone metastasis in clear cell renal cell carcinoma. This research aims to advance understanding of metastatic mechanisms...
- The National Institute on Aging awarded H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. $707,102 on July 1, 2026, under the Aging Research program (CFDA 93.866) to investigate age-induced mechanisms of therapeutic resistance in lung cancer. The research focuses on how systemic metabolic reprogramming associated with aging contributes to lung cancer progression and resistance to chemotherapy and targeted therapies. The project will examine the role of glucocorticoid hormones,...
- The U.S. Department of Defense's Defense Health Agency awarded a $481,749 Project Grant to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. (Moffitt Cancer Center) under the Military Medical Research and Development program (CFDA 12.420). The grant, effective September 30, 2023 through September 29, 2026, will support research to dissect the spatial molecular architecture of the transformed cutaneous T cell lymphoma tumor microenvironment, with the goal of identifying novel...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. a Project Grant of $433,256 under the Cancer Treatment Research program (CFDA 93.395) for the period of September 1, 2025 through August 31, 2027. This award supports exploratory research into the role of antisense ribonucleic acids (asRNAs) in melanoma development and transformation. The project will deliver scientific research and analysis focused on...
The National Institute for Minority Health and Health Disparities awarded H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. $811,939 on August 4, 2026, under the Minority Health and Health Disparities Research program (CFDA 93.307) to investigate accelerated aging biomarkers in cancer patients with HIV. The award funds prospective identification and molecular analysis of 500 cancer patients—250 with HIV and 250 without HIV—recruited from Moffitt Cancer Center, plus 250 people with HIV without cancer from the HIV Fighter Registry partnership. The research tests whether exposure to multi-level stressors (individual-level factors such as perceived job stress and neighborhood-level factors such as poverty concentration) drives accelerated aging patterns—measured through DNA methylation and clonal hematopoiesis—that mediate poor cancer outcomes among people with HIV in the southeastern United States. The work addresses an evidence gap in understanding how biological aging changes stemming from social stressors contribute to elevated cancer mortality in this population. Performance occurs in Tampa, Florida with a period of performance through December 31, 2030. The award is a Project Grant, a standard NIH assistance type supporting time-limited research projects evaluated on scientific merit by peer review and the National Advisory Council on Minority Health and Health Disparities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $811.9k | 8/5/26 |